Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lonidamine: a non-mutagenic antitumor agent.

R Forster1, A Campana, E D'Onofrio

  • 1F. Angelini Research Institute, Rome, Italy.

Carcinogenesis
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trainee as trainer in paediatric laparoscopic appendicectomy.

Annals of the Royal College of Surgeons of England·2024
Same author

Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection.

Microbiology spectrum·2024
Same author

Medical Journals and Practitioners.

The Homoeopathic physician·2023
Same author

Quantifying graft impingement in anterior cruciate ligament reconstruction.

The Knee·2022
Same author

Validation of the Manchester spoken language development scale (MSLDS).

Cochlear implants international·2020
Same author

Water-gated organic field effect transistors - opportunities for biochemical sensing and extracellular signal transduction.

Journal of materials chemistry. B·2020

Lonidamine, an antitumour indazole-carboxylic acid, showed no mutagenic activity in comprehensive genetic toxicity tests. This lack of mutagenicity suggests a reduced risk of secondary cancers and heritable genetic damage in cancer patients.

Area of Science:

  • Pharmacology
  • Toxicology
  • Oncology

Background:

  • Lonidamine is an indazole-carboxylic acid derivative with demonstrated antitumour properties.
  • Assessing the mutagenicity of novel anticancer agents is crucial for patient safety and therapeutic efficacy.

Purpose of the Study:

  • To comprehensively evaluate the potential mutagenicity of lonidamine using a battery of in vitro and in vivo genotoxicity assays.
  • To determine if lonidamine poses a risk for inducing genetic damage.

Main Methods:

  • Bacterial reverse mutation assay (Ames test).
  • In vitro mammalian cell assays (HPRT gene mutation, chromosomal aberration).
  • In vivo assays (micronucleus test, dominant lethal test).

Main Results:

Related Experiment Videos

  • Lonidamine tested negative in bacterial gene mutation assays.
  • No evidence of gene mutation induction in CHO cells.
  • No chromosomal damage observed in vitro or in vivo.
  • Negative results in somatic and germinal cell genotoxicity tests.

Conclusions:

  • Lonidamine exhibits a lack of mutagenic and genotoxic potential across multiple test systems.
  • Its mechanism of action appears to target cellular energy processes, not DNA or cell division machinery.
  • The absence of mutagenicity suggests lonidamine may offer therapeutic advantages with a lower risk of secondary malignancies and heritable genetic damage.